2022
Foundation laid
Carelight founded; OPM development begins.
Validated performance across movement and skin tones, AI-powered OPM ensures clinical accuracy.
Backed by decades of research, 100+ published studies and 30+ PhD graduates, Carelight’s OPM platform is built on rigorous science, not assumptions.
More than two decades of innovation, built on peer-
reviewed science.
Independent evidence proving accuracy and reliability across diverse patient groups.
A sustained pipeline of expertise across photonics, biomed and data science.
Active pathways toward CE marking and FDA clearance for global deployment.
Our data shows what conventional sensors can’t: AI-powered accuracy that holds across skin tones, patient groups and real-world conditions.
Validated accuracy where pulse oximetry and consumer wearables often fail.
AI-enhanced algorithms maintain reliable readings during activity, exercise and daily life.
Tested across demographics to ensure equity in every patient signal.
High-definition pulsatile wave analysis, with AI isolating fine features missed by standard PPG.
Ongoing studies are validating OPM’s AI-powered accuracy across diverse patients, hospitals and conditions – proving robustness in real-world clinical care.
Multi-site study validating HR and HRV accuracy across melanin levels and demographics.
Participants → 500+
Sites → 5 hospitals
Real-world performance testing during activity, exercise, and sleep monitoring, using AI-driven filtering to maintain accuracy.
Participants → 150+
Sites → 2 research centres
Continuous vital sign tracking for cardiac surgery patients transitioning from ICU to home care.
Participants → 200+
Sites → 4 hospitals
Safety and efficacy evaluation for continuous monitoring in paediatric cardiac patients.
Participants → 100+
Sites → 3 children’s hospitals
Peer-reviewed research demonstrating the clinical efficacy, inclusivity and AI-driven innovation behind OPM.
In press Nature Scientific Reports, https://doi.org/10.1038/s41598-025-31116-9
Our multidisciplinary team brings together expertise in biomedical optics, AI-driven signal processing, clinical medicine and regulatory science. By collaborating with leading universities and clinical centres worldwide, we’re advancing the future of non-invasive, continuous monitoring.
Upcoming studies and regulatory milestones on the path to clinical deployment.
Carelight founded; OPM development begins.
First fully wearable prototype tested.
Hypoxia clinical study completed.
First product prototype developed; FDA 510(k) documentation begins.
FDA 510(k) submission for wrist-worn device; CE marking expected before year end.